Vaccines

Vaccine programs demand flawless execution at unprecedented scale, yet outsourcing to high-volume facilities introduces risks: lot variability, cold chain breaks, and aseptic breaches that can compromise immunogenicity or trigger recalls.

Aventiq Bio acts as your reliability guardian - delivering independent oversight for antigen integrity, fill-finish mastery, and global access in India's dominant ecosystem.

India's Vaccine Dominance – Scale with Precision Potential

India's facilities are unrivaled for volume, with WHO-prequalified sites producing recombinant, subunit, viral vector, and live/attenuated vaccines at billion-dose levels. Strengths include robust cold chain networks, adjuvant expertise, and rapid response capability. The ecosystem supports global tenders and emerging innovations including mRNA vaccine platforms and adjuvanted subunit technologies.

• Lot-to-Lot Consistency Variability

  Batch #1 differing from Batch #100 in potency or impurities at massive scale.

• Thermal Stability Profiles

  Antigen degradation during storage/transport in diverse climates

• Aseptic Integrity at Speed

  High-speed lines (600+ vials/min) prone to subtle sterility breaches missed in routine audits.

• Adjuvant-Antigen Compatibility Issues

  Poor integration leading to reduced immunogenicity or stability.

• Analytical Bridge to Potency

  In-vitro assays failing to correlate with clinical immune responses